Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study
Abstract We conducted a multicenter study on anti-programmed cell death-1 monoclonal antibodies (anti-PD-1 mAbs) before/after allogeneic hematopoietic cell transplantation (allo-HCT) for Hodgkin lymphoma. Anti-PD-1 mAbs were administered to 25 patients before allo-HCT and to 20 after allo-HCT. In pre-allo-HCT setting, the median interval from the last administration to allo-HCT was 59 days. After allo-HCT, 12 patients developed non-infectious febrile syndrome requiring high-dose corticosteroid. The cumulative incidences of grade II–IV acute graft-versus-host disease (aGvHD) were 47.1%. Eight patients who had GvHD prophylaxis with post-transplant cyclophosphamide (PTCy) had less frequent aGvHD (grade II–IV, 14.6% versus 58.8%; P = 0.086). The 1 year overall survival (OS), relapse/progression, and non-relapse mortality rates were 81.3%, 27.9%, and 8.4%. In post-allo-HCT setting, the median interval from allo-HCT to the first administration was 589 days. The overall and complete response rates were 75% and 40%. At 100 days after anti-PD-1 therapy, the cumulative incidences of grade II–IV aGvHD, moderate-to-severe chronic GvHD, and grade 3–4 immune-related toxicity were 15.0%, 30.0%, and 30.0%. While the 1 year relapse/progression rate was 47.4%, the 1 year OS probability was 89.7%. In conclusion, immune-related complications were frequent despite modifications of GvHD prophylaxis or anti-PD-1 mAb dosing. In anti-PD-1-mAb-pretreated patients, PTCy-based GvHD prophylaxis may be effective..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
International journal of hematology - 112(2020), 5 vom: 03. Aug., Seite 674-689 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ito, Ayumu [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Allogeneic hematopoietic cell transplantation |
| doi: |
10.1007/s12185-020-02960-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR041410696 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR041410696 | ||
| 003 | DE-627 | ||
| 005 | 20230520005757.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201102s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12185-020-02960-4 |2 doi | |
| 035 | |a (DE-627)SPR041410696 | ||
| 035 | |a (SPR)s12185-020-02960-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.86 |2 bkl | ||
| 100 | 1 | |a Ito, Ayumu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract We conducted a multicenter study on anti-programmed cell death-1 monoclonal antibodies (anti-PD-1 mAbs) before/after allogeneic hematopoietic cell transplantation (allo-HCT) for Hodgkin lymphoma. Anti-PD-1 mAbs were administered to 25 patients before allo-HCT and to 20 after allo-HCT. In pre-allo-HCT setting, the median interval from the last administration to allo-HCT was 59 days. After allo-HCT, 12 patients developed non-infectious febrile syndrome requiring high-dose corticosteroid. The cumulative incidences of grade II–IV acute graft-versus-host disease (aGvHD) were 47.1%. Eight patients who had GvHD prophylaxis with post-transplant cyclophosphamide (PTCy) had less frequent aGvHD (grade II–IV, 14.6% versus 58.8%; P = 0.086). The 1 year overall survival (OS), relapse/progression, and non-relapse mortality rates were 81.3%, 27.9%, and 8.4%. In post-allo-HCT setting, the median interval from allo-HCT to the first administration was 589 days. The overall and complete response rates were 75% and 40%. At 100 days after anti-PD-1 therapy, the cumulative incidences of grade II–IV aGvHD, moderate-to-severe chronic GvHD, and grade 3–4 immune-related toxicity were 15.0%, 30.0%, and 30.0%. While the 1 year relapse/progression rate was 47.4%, the 1 year OS probability was 89.7%. In conclusion, immune-related complications were frequent despite modifications of GvHD prophylaxis or anti-PD-1 mAb dosing. In anti-PD-1-mAb-pretreated patients, PTCy-based GvHD prophylaxis may be effective. | ||
| 650 | 4 | |a Anti-PD-1 monoclonal antibody |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immune checkpoint inhibitor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hodgkin lymphoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Allogeneic hematopoietic cell transplantation |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kim, Sung-Won |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuoka, Ken-ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakita, Toshiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Inamoto, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Toubai, Tomomi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujiwara, Shin-ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Fukaya, Masafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kondo, Tadakazu |e verfasserin |4 aut | |
| 700 | 1 | |a Sugita, Junichi |e verfasserin |4 aut | |
| 700 | 1 | |a Nara, Miho |e verfasserin |4 aut | |
| 700 | 1 | |a Katsuoka, Yuna |e verfasserin |4 aut | |
| 700 | 1 | |a Imai, Yosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nakazawa, Hideyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kawashima, Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Rika |e verfasserin |4 aut | |
| 700 | 1 | |a Ishii, Arata |e verfasserin |4 aut | |
| 700 | 1 | |a Onizuka, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Takemura, Tomonari |e verfasserin |4 aut | |
| 700 | 1 | |a Terakura, Seitaro |e verfasserin |4 aut | |
| 700 | 1 | |a Iida, Hiroatsu |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamae, Mika |e verfasserin |4 aut | |
| 700 | 1 | |a Higuchi, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, Shinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshioka, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Togitani, Kazuto |e verfasserin |4 aut | |
| 700 | 1 | |a Kawano, Noriaki |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Ritsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Suzumiya, Junji |e verfasserin |4 aut | |
| 700 | 1 | |a Izutsu, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Teshima, Takanori |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuda, Takahiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of hematology |d Tokyo [u.a.] : Springer, 1995 |g 112(2020), 5 vom: 03. Aug., Seite 674-689 |w (DE-627)SPR025085697 |w (DE-600)2028991-1 |x 1865-3774 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2020 |g number:5 |g day:03 |g month:08 |g pages:674-689 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12185-020-02960-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.86 |q ASE |
| 951 | |a AR | ||
| 952 | |d 112 |j 2020 |e 5 |b 03 |c 08 |h 674-689 | ||